Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 756 participants.

Also called NCT03855826

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 756 participants (planned count) (from the registry)
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd. (from the registry)
Registry
  • NCT NCT03855826
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03855826. Randomized; no masking; primary purpose treatment. Start 2019-01-15 (actual); primary completion 2020-01-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.
Condition
Ventricular Tachycardia
Intervention (Drug)
Nifekalant hydrochloride
Intervention (Drug)
Amiodarone
Lead sponsor
Sichuan Baili Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03855826
Content hash
39dcfee208d7304e23af5bcba178e7bfc26f5d680541341563c4140e6adeb5d1